Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates strong financial performance with increased sales and gross profit, despite a net loss. Management expressed confidence in future revenue growth, projecting over $100 million in 2026, supported by new technologies and product lines. While there are concerns about rising operational expenses and potential margin pressures, the optimistic guidance and strategic repositioning are positive indicators. The Q&A section reinforced this outlook with discussions on technological advantages and market expansion. Overall, these factors suggest a likely positive stock price movement, although the lack of market cap data limits precise impact assessment.
Net Sales (4Q 2025) $20.7 million, increased 2% year-over-year. Reasons: Accelerating demand trends, strong end-user demand, broader adoption of Ambiq solutions, and customers upgrading to Apollo5.
Non-GAAP Gross Profit (4Q 2025) $9.4 million, increased 75.5% year-over-year. Reasons: Strategic repositioning, favorable product mix, and higher sales to customers deploying multiple edge AI capabilities.
Non-GAAP Gross Margin (4Q 2025) 45.5%, expanded almost 20 percentage points year-over-year. Reasons: Favorable product mix and strategic repositioning.
Non-GAAP R&D Expense (4Q 2025) $9.3 million, up 33% year-over-year. Reasons: Additional investment to support product development for Atomiq and Apollo families.
Non-GAAP SG&A Expense (4Q 2025) $7.3 million, up 19.7% year-over-year. Reasons: Public company costs, strategic investments in sales and marketing, and higher incentive compensation.
Other Income (4Q 2025) $1.3 million, up $1.1 million year-over-year. Reasons: Interest income earned on IPO proceeds.
Non-GAAP Net Loss Attributable to Common Stockholders (4Q 2025) $5.9 million, a $1.7 million improvement year-over-year. Reasons: Improved gross profit and strategic repositioning.
Full Year 2025 Gross Profit Increased 32.1% year-over-year despite a 4.7% decrease in net sales. Reasons: Strategic repositioning and stronger margins.
Apollo510 Lite, Apollo510B, Apollo330: Launched to support advanced edge AI applications.
HeliaAOT and HeliaRT: Introduced as AI runtime powered by Helia Core AI kernel library.
Atomiq: Announced as the first SPOT family built on a FinFET process, enabling operation down to 300 millivolts for ultra-low power and sophisticated AI capabilities.
Apollo340 and Atomiq120: Development accelerated to expand into new high-opportunity segments and support advanced AI workloads.
Wearables: Expanded into new form factors like rings and eyewear, broadening the addressable market.
Medical, Industrial, and Smart Home: Expanded customer base and design funnel, with applications in cardiac monitors, senior care devices, predictive maintenance, and energy optimization.
RONDS Partnership: Collaborated to deploy large-scale, always-on battery-powered sensors for industrial edge applications.
IPO and Follow-on Offering: Completed IPO and follow-on offering, raising $140.3 million and $76.8 million respectively, strengthening cash position for growth initiatives.
Strategic Repositioning: Shifted focus to high-value customers and reduced exposure to Mainland China, improving gross profit and margins.
R&D and SG&A Investments: Increased R&D and SG&A expenses to support product development and strategic growth priorities.
Edge AI Adoption: Focused on enabling advanced edge AI capabilities across diverse markets, leveraging SPOT platform.
Product Roadmap Acceleration: Accelerated development of Apollo and Atomiq families to capture market opportunities.
Market Diversification: Targeted expansion into high-value markets like medical, industrial, and smart home sectors.
Regulatory and Industrial Design Cycles: Longer design cycles in regulated and industrial environments could delay product adoption and revenue realization.
Supply Chain Pressures: Potential broader industry cost dynamics and supply chain pressures may impact gross margins.
Increased Operating Expenses: Non-GAAP operating expenses are expected to rise by approximately $30 million in 2026, driven by accelerated product development and IP purchases, which could strain financials.
Dependence on New Product Launches: The company's growth heavily relies on the successful launch and adoption of new products like Atomiq and Apollo families.
Customer Concentration Risk: A significant portion of revenue is tied to a few large customers, increasing vulnerability to changes in their demand or business strategies.
Market Competition: Intensifying competition in the edge AI market could pressure pricing and market share.
Economic Uncertainty: Broader economic uncertainties could impact customer spending and demand for edge AI solutions.
2026 Revenue Growth: Ambiq expects significant top-line growth in 2026, driven by new model launches, ramping up of a scaled global customer, higher volumes from recent customer introductions, and continued adoption of Apollo5.
Product Development and Launches: The company is accelerating development of both Atomiq and Apollo product families, with plans to start development of Apollo340 and Atomiq120 in 2026. These products are designed to expand into new high-opportunity segments and support advanced AI capabilities.
Market Trends and Expansion: Edge AI adoption is expected to accelerate in 2026, with increasing demand for sophisticated edge AI capabilities in wearables, medical devices, industrial markets, and smart homes. Wearables are evolving into personal health platforms, and new form factors like rings and eyewear are broadening the addressable market.
Financial Guidance for Q1 2026: Net sales are expected to range between $21 million and $22 million. Non-GAAP gross margin is projected between 44% and 45%. Non-GAAP operating expenses are estimated at $18 million to $18.5 million, reflecting increased investment in strategic growth priorities.
Long-Term Growth Drivers: Ambiq is investing in R&D, software, and go-to-market initiatives to capture a larger share of the expanding edge AI market. The Atomiq product family is expected to contribute meaningfully to growth starting in 2028.
The selected topic was not discussed during the call.
The earnings call indicates strong financial performance with increased sales and gross profit, despite a net loss. Management expressed confidence in future revenue growth, projecting over $100 million in 2026, supported by new technologies and product lines. While there are concerns about rising operational expenses and potential margin pressures, the optimistic guidance and strategic repositioning are positive indicators. The Q&A section reinforced this outlook with discussions on technological advantages and market expansion. Overall, these factors suggest a likely positive stock price movement, although the lack of market cap data limits precise impact assessment.
The earnings call reveals several negative factors: decreased margins, increased costs, and a decline in net earnings. The Q&A highlights uncertainties in North America and lack of clarity on growth potential. Despite some growth prospects in South America, the lack of positive guidance and weak performance in the U.S. contribute to a negative sentiment. Additionally, the management's evasive responses to critical questions further undermine confidence.
The earnings call presented mixed signals: a strategic shift away from China led to reduced sales there, but overall revenue increased sequentially. Gross profit improved YoY, but operating expenses rose sequentially. The Q&A revealed optimism about edge AI growth and a stable gross margin outlook, yet management's vague responses on key metrics and timelines dampened sentiment. Despite some positive financial metrics, the lack of clear guidance and ongoing losses suggest a neutral stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.